The development speed paradox: Can increasing development speed reduce R&D productivity?

Drug Discovery Today

Volumn 19, Issue 3, 2014, Pages 209-214

  Lendrem, Dennis W ^a   Lendrem, B Clare ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COST; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG RESEARCH; PRODUCTIVITY; REVIEW; DRUG DESIGN; HUMAN; NONBIOLOGICAL MODEL; ORGANIZATION AND MANAGEMENT; RESEARCH; TIME;

DRUG DESIGN; DRUG INDUSTRY; EFFICIENCY, ORGANIZATIONAL; HUMANS; MODELS, ORGANIZATIONAL; RESEARCH; TIME FACTORS;

EID: 84896398034     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.09.002     Document Type: Short Survey

References (25)

1. J.A. DiMasi The value of improving the productivity of the drug development process: faster times and better decisions Pharmacoeconomics 20 2002 1 10
2. K.A. Getz, and A. De Bruin Breaking the development speed barrier: assessing successful practices of the fastest drug development companies Drug Inf. J. 34 2000 725 736 (Pubitemid 30659506)
3. C.-F. Burman, and S. Senn Examples of option values in drug development Pharm. Stat. 2 2003 113 125
4. R. McKinnon Crisis? What Crisis? A Fresh Diagnosis of Pharma's R&D Productivity Crunch 2004 Marrakon Associates Available at: http://marakon.com/ images/uploads/documents/Crisis-What-Crisis-A-Fresh-Diagnosis-of-Big-Pharmas-RD- Productivity-Crunch-0513.pdf
5. S.M. Paul et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
6. R.W. Peck Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development Drug Discov. Today 12 2007 289 294 (Pubitemid 46486663)
7. H.G. Grabowski Are the economics of pharmaceutical R&D changing? Pharmacoeconomics 22 Suppl. 2 2004 15 24
8. Hu, M., Schultz, K., Sheu, J., and Tschopp, D. (2007) The innovation gap in pharmaceutical drug discovery & new models for R&D success. Kellogg School of Management.
9. Tufts Center for the Study of Drug Development Outlook 2009 Tufts Center for the Study of Drug Development Boston, MA Available at: http://csdd.tufts.edu
10. E. David et al. Pharmaceutical R&D: the road to positive returns Nat. Rev. Drug Discov. 8 2009 609 610
11. J.C. Gittins Stochastic models for the planning of pharmaceutical research J. Stat. Theory Appl. 2 2003 198 214
12. O. Gassmann et al. Leading Pharmaceutical Innovation: Trends and Drivers for Growth in the Pharmaceutical Industry 2008 Springer
13. F. Pammolli et al. The productivity crisis in pharmaceutical R&D Nat. Rev. Drug Discov. 10 2011 428 438
14. J.W. Scannell et al. Diagnosing the decline in pharmaceutical R&D efficiency Nat. Rev. Drug Discov. 11 2012 191 200
15. M.J. Rogers et al. Real options based analysis of optimal pharmaceutical research and development portfolios Ind. Eng. Chem. Res. 41 2002 6607 6620 (Pubitemid 35429854)
16. J.F. Pritchard et al. Making better drugs: decision gates in non-clinical drug development Nat. Rev. Drug Discov. 2 2003 542 553 (Pubitemid 37361746)
17. S. Senn Some statistical issues in project prioritization in the pharmaceutical industry Stat. Med. 15 1996 2689 2702 (Pubitemid 27011051)
18. W. Feller An Introduction to Probability Theory and its Applications vol 2 2008 John Wiley & Sons
19. D.W. Lendrem, and B.C. Lendrem Torching the haystack: modelling fast-fail strategies in drug development Drug Discov. Today 18 2013 331 336
20. N. Dimitri An assessment of R&D productivity in the pharmaceutical industry Trends Pharmacol. Sci. 32 2011 683 685
21. D.W. Lendrem More haste, less development speed Scr. Mag. April 1995 22 23
22. E.E. Deming Out of the Crisis 1986 MIT Press Cambridge
23. J. Arrowsmith Trial watch: Phase II failures: 2008-2010 Nat. Rev. Drug Discov. 10 2011 328 329
24. J. Arrowsmith Trial watch: Phase III and submission failures: 2007-2010 Nat. Rev. Drug Discov. 10 2011 87
25. D.W. Light, and J.R. Lexchin Pharmaceutical research and development: what do we get for all that money? BMJ Online 345 2012 e4348